Key Segmentation
By Dosage Form
-
Capsules
-
Tablets
-
Oral Solution
-
Extended-Release Tablets
-
Others
By Type
-
Generic
-
Branded
By Application
-
Epilepsy
-
Neuropathic Pain
-
Restless Legs Syndrome
-
Postherpetic Neuralgia
-
Others
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
-
Others
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Rising global prevalence of epilepsy affecting approximately 50 million people and neuropathic pain affecting 9.2% of the general population.
The Gabapentin Market was valued at USD 2.56 Billion in 2025.
The Gabapentin Market is expected to grow at a CAGR of 4.75% from 2026 to 2035.
North America dominated the Gabapentin Market with approximately 36.62% of revenues in 2025.
Capsules dominated the Gabapentin Market with approximately 55.27% share in 2025.